Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 428.e1-428.e5

  Ziebell, Morten ^a   Khalid, Usman ^a   Klein, Anders B ^a   Aznar, Susana ^a   Thomsen, Gerda ^a   Jensen, Peter ^a   Knudsen, Gitte M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

BDNF; Dopamine tranporter; PE2I; SPECT

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE TRANSPORTER; IODINE 123; POTASSIUM PERCHLORATE;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 82755161923     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.11.010     Document Type: Article

References (35)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol 2003, 60:387-392.
2. Abi-Dargham A., Gandelman M.S., DeErausquin G.A., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., Laruelle M., Charney D.S., Hoffer P.B., Neumeyer J.L., Innis R.B. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J. Nucl. Med 1996, 37:1129-1133.
3. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci 2001, 21:6853-6861.
4. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
5. Booij J., Habraken J.B., Bergmans P., Tissingh G., Winogrodzka A., Wolters E.C., Janssen A.G., Stoof J.C., van Royen E.A. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J. Nucl. Med 1998, 39:1879-1884.
6. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol 2008, 11:1169-1180.
7. Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci 1997, 17:2295-2313.
8. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5104-5108.
9. Gyarfas T., Knuuttila J., Lindholm P., Rantamaki T., Castren E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell. Mol. Neurobiol 2010, 30:361-368.
10. Hall H., Halldin C., Guilloteau D., Chalon S., Emond P., Besnard J., Farde L., Sedvall G. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage 1999, 9:108-116.
11. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol 2000, 166:127-135.
12. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab 2007, 27:1533-1539.
13. Innis R.B., Seibyl J.P., Scanley B.E., Laruelle M., Abi-Dargham A., Wallace E., Baldwin R.M., Zea-Ponce Y., Zoghbi S., Wang S. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11965-11969.
14. Jasinska-Myga B., Putzke J.D., Wider C., Wszolek Z.K., Uitti R.J. Depression in Parkinson's disease. Can. J. Neurol. Sci 2010, 37:61-66.
15. Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., Knudsen G.M., Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol 2010, 1-7.
16. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Maetzler W., Wittorf A., Soekadar S., Richartz E., Koehler N., Bartels M., Buchkremer G., Schott K. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res 2007, 41:387-394.
17. Meredith G.E., Callen S., Scheuer D.A. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002, 949:218-227.
18. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett 1999, 270:45-48.
19. Morrish P.K. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?. Mov. Disord 2003, 18(suppl 7):S63-S70.
20. O'Brien J.T., McKeith I.G., Walker Z., Tatsch K., Booij J., Darcourt J., Marquardt M., Reininger C. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br. J. Psychiatry 2009, 194:34-39.
21. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J. Med 2009, 361:1268-1278.
22. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999, 10:557-561.
23. Pinborg L.H., Ziebell M., Frokjaer V.G., de Nijs R., Svarer C., Haugbol S., Yndgaard S., Knudsen G.M. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J. Nucl. Med 2005, 46:1119-1127.
24. Pirker W., Asenbaum S., Bencsits G., Prayer D., Gerschlager W., Deecke L., Brucke [123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord 2000, 15:1158-1167.
25. Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M., Brucke T. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov. Disord 2002, 17:45-53.
26. Rasmussen P., Brassard P., Adser H., Pedersen M.V., Leick L., Hart E., Secher N.H., Pedersen B.K., Pilegaard H. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp. Physiol 2009, 94:1062-1069.
27. Scalzo P., Kummer A., Bretas T.L., Cardoso F., Teixeira A.L. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J. Neurol 2010, 257:540-545.
28. Sossi V., Dinelle K., Topping G.J., Holden J.E., Doudet D., Schulzer M., Ruth T.J., Stoessl A.J., de la Fuente-Fernandez R. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem 2009, 109:85-92.
29. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem 1992, 59:99-106.
30. Trajkovska V., Marcussen A.B., Vinberg M., Hartvig P., Aznar S., Knudsen G.M. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res. Bull 2007, 73:143-149.
31. Tsukahara T., Takeda M., Shimohama S., Ohara O., Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995, 37:733-739.
32. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Zoghbi S.S., Baldwin R.M., Innis R.B. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am. J. Geriatr. Psychiatry 2002, 10:36-43.
33. Williams S.N., Undieh A.S. Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport 2009, 20:606-610.
34. Ziebell M., Pinborg L.H., Thomsen G., de Nijs R., Svarer C., Wagner A., Knudsen G.M. MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J. Nucl. Med. Technol 2010, 38:61-68.
35. Ziebell M., Thomsen G., Knudsen G.M., de Nijs R., Svarer C., Wagner A., Pinborg L.H. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:101-109.